PAI
Palo Alto Investors Portfolio holdings
AUM $470M
1-Year Return
2.57%
This Quarter Return
-5.28%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$525M
AUM Growth
-$120M
(-19%)
Cap. Flow
-$70.1M
Cap. Flow
% of AUM
-13.35%
Top 10 Holdings %
Top 10 Hldgs %
74.78%
Holding
46
New
3
Increased
9
Reduced
11
Closed
2
Top Buys
| 1 |
Agios Pharmaceuticals
AGIO
|
+$8.1M |
| 2 |
Dyne Therapeutics
DYN
|
+$3.49M |
| 3 |
NovoCure
NVCR
|
+$3.35M |
| 4 |
AnaptysBio
ANAB
|
+$3.29M |
| 5 |
Biogen
BIIB
|
+$2.02M |
Top Sells
| 1 |
Insmed
INSM
|
+$47M |
| 2 |
United Therapeutics
UTHR
|
+$15.6M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$15.4M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$5.38M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
+$2.79M |
Sector Composition
| 1 | Healthcare | 97.86% |
| 2 | Financials | 2.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$30.6B
| $75.3M | 14.34% |
987,153
-616,312
| -38% | -$47M |
|
|
2
BioMarin Pharmaceuticals
BMRN
$10.4B
| $70.1M | 13.34% |
991,207
-76,059
| -7% | -$5.38M |
|
3
Amicus Therapeutics
FOLD
$2.46B
| $59.9M | 11.41% |
7,345,002
-317,477
| -4% | -$2.59M |
|
4
Acadia Pharmaceuticals
ACAD
$4.08B
| $44.2M | 8.43% |
2,663,925
-84,674
| -3% | -$1.41M |
|
|
5
United Therapeutics
UTHR
$18.3B
| $32.4M | 6.18% |
105,228
-50,486
| -32% | -$15.6M |
|
|
6
Biogen
BIIB
$21.2B
| $28M | 5.34% |
204,923
+14,775
| +8% | +$2.02M |
|
|
7
Alnylam Pharmaceuticals
ALNY
$59.2B
| $22.5M | 4.29% |
83,488
-57,193
| -41% | -$15.4M |
|
8
PTC Therapeutics
PTCT
$4.82B
| $20.6M | 3.92% |
404,196
+17,783
| +5% | +$906K |
|
9
Prothena Corp
PRTA
$434M
| $20.5M | 3.91% |
1,659,734
-78,230
| -5% | -$968K |
|
|
10
AnaptysBio
ANAB
$554M
| $19M | 3.61% |
1,020,713
+176,742
| +21% | +$3.29M |
|
|
11
NovoCure
NVCR
$1.42B
| $17.9M | 3.4% |
1,002,061
+187,870
| +23% | +$3.35M |
|
12
Sarepta Therapeutics
SRPT
$1.78B
| $13.4M | 2.56% |
210,258
| – | – |
|
13
eHealth
EHTH
$118M
| $11.3M | 2.14% |
1,684,336
-193,791
| -10% | -$1.29M |
|
14
Iovance Biotherapeutics
IOVA
$803M
| $10.7M | 2.04% |
3,211,314
+169,629
| +6% | +$565K |
|
15
STAAR Surgical
STAA
$1.35B
| $9.26M | 1.76% |
525,017
+24,242
| +5% | +$427K |
|
|
16
Agios Pharmaceuticals
AGIO
$2.12B
| $8.1M | 1.54% |
+276,578
| New | +$8.1M |
|
17
Alkermes
ALKS
$4.6B
| $7.31M | 1.39% |
221,513
-67,795
| -23% | -$2.24M |
|
18
Gossamer Bio
GOSS
$680M
| $6.9M | 1.31% |
6,276,893
-200
| -0% | -$220 |
|
19
Align Technology
ALGN
$9.38B
| $6M | 1.14% |
37,772
| – | – |
|
20
Syndax Pharmaceuticals
SNDX
$1.27B
| $5.46M | 1.04% |
444,367
+39,174
| +10% | +$481K |
|
|
SLRN
21
DELISTED
ACELYRIN
SLRN
| $4.43M | 0.84% |
1,792,895
| – | – |
|
|
22
Dyne Therapeutics
DYN
$1.87B
| $3.49M | 0.66% |
+333,391
| New | +$3.49M |
|
23
Mirum Pharmaceuticals
MIRM
$3.67B
| $2.91M | 0.56% |
64,700
| – | – |
|
24
Edwards Lifesciences
EW
$44.1B
| $2.86M | 0.54% |
39,473
| – | – |
|
|
VERV
25
DELISTED
Verve Therapeutics
VERV
| $2.63M | 0.5% |
575,817
| – | – |
|